Accueil / Communiqués / Accenture Expands Platform for Drug Discovery and Innovation with Creation of Life Sciences Partner Ecosystem

Accenture Expands Platform for Drug Discovery and Innovation with Creation of Life Sciences Partner Ecosystem

Monday, November 26th 2018 at 1:29pm UTC

NEW YORK & LAS VEGAS–(BUSINESS WIRE)– Accenture (NYSE:ACN) has created an
open partner ecosystem
designed to help independent software vendors
(ISVs) and life sciences companies team more effectively to accelerate
drug discovery efforts and, ultimately, improve patient outcomes.

The ecosystem is an integral part of the cloud-based
informatics research platform
that Accenture and Merck (known as MSD
outside the United States and Canada) are developing. Built on Amazon
Web Services and supported by ongoing work between Accenture and AWS
through the Accenture
AWS Business Group
, the platform is designed to help life sciences
organizations improve productivity, efficiency and innovation in drug
discovery.

Through the new ecosystem, ISVs will be able to leverage the platform’s
use of open, industry-standard-based application programming interfaces
(APIs) to easily integrate technology components, applications and
content into the platform. This will enable life sciences companies to
give researchers access to innovative, best-of-breed capabilities, such
as small-molecule and biological-entity registration, biological assay
data capture, genomics data analysis, image storage and analysis, and
artificial intelligence.

These capabilities will be available to life sciences companies within a
common informatics framework that handles core infrastructure
requirements such as data ingestion and cleansing, security and IP
management, request management workflow, enterprise search, data
governance and collaboration environments.

“While our life sciences clients need to be nimble in their ability to
provide scientific researchers with leading technology capabilities,
they are faced with legacy IT systems and complex processes that make
integrating new solutions challenging,” said Brad Michel, managing
director of Accenture
Scientific Informatics Services
. “The new ecosystem we’re creating
around the Accenture research platform will offer immediate access to
innovative tools, enabling life sciences companies to significantly
reduce the time, expense and effort required to implement new technology
solutions—accelerating drug discovery and delivering solutions to
patients faster.”

Hal Stern, associate vice president of IT Engineering at Merck Research
Labs, said, “One of the key reasons we chose to collaborate with
Accenture on the development of the research platform is because of
their ability to enable and accelerate this technology partner
ecosystem. Through the ecosystem, we are creating an environment that
will make it easier for life sciences companies to on-board innovations
from leading-edge technology vendors that really can advance science —
whether experiment design and data management, visualization, or machine
learning capabilities to improve decision making — and bring all this
information together in a common platform and infrastructure for drug
discovery.”

Accenture is currently working with more than 30 ISVs and organizations
to integrate their technology and content into Accenture’s research
platform. These include the following ISVs who will be highlighting
their work with Accenture in a developer workshop being held in Las
Vegas on Nov. 28 in conjunction with AWS re:Invent 2018:

  • ChemAxon,
    a provider of highly integrable software with chemical and biological
    intelligence for the life sciences, flavors, cosmetics, new materials,
    petro- and agro-chemistry industries;
  • Clarivate
    Analytics
    , a global company offering trusted insights and
    analytics to help companies accelerate the pace of innovation,
    including a comprehensive suite of solutions for life science
    professionals;
  • Dotmatics,
    a company specializing in scientific informatics solutions for the
    management, query and visualization of chemistry and biology data;
  • SciBite,
    a provider of text mining, semantics and data intelligence within the
    biopharma and biotech industries;
  • Scilligence,
    a company that delivers cross-platform, mobile cheminformatics and
    bioinformatics solutions; and
  • Vyasa,
    a provider of scalable, deep-learning software and analytics for life
    sciences and healthcare organizations.

For more information on becoming an ecosystem partner, visit accenture.com/ResearchEcosystem.

The new research platform and the ecosystem are just a few of the
solutions offered by the Accenture Life Sciences R&D practice to help
its clients deliver better outcomes for patients. These solutions
include services and platforms focused on building more efficient and
effective R&D models and fostering collaboration within the industry,
from early-stage research to regulatory approval and throughout the
product lifecycle. For more information about our research services, click
here
.

About Accenture
Accenture is a leading global professional
services company, providing a broad range of services and solutions in
strategy, consulting, digital, technology and operations. Combining
unmatched experience and specialized skills across more than 40
industries and all business functions — underpinned by the world’s
largest delivery network — Accenture works at the intersection of
business and technology to help clients improve their performance and
create sustainable value for their stakeholders. With 459,000 people
serving clients in more than 120 countries, Accenture drives innovation
to improve the way the world works and lives. Visit us at www.accenture.com.

Contacts

Cam Granstra
Accenture
+1 312-693-5992
cameria.l.granstra@accenture.com

Source: Accenture


Voir aussi

Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy

Supernus Pharmaceuticals, Inc. — Friday, December 14th 2018 at 9:02pm UTC ROCKVILLE, Md., Dec. 14, …